Case Report ISSN 2641-4333

Neurology - Research & Surgery

Neural Signatures of Addiction: From Brain Mapping to Clinical Monitoring

Casazza Krista[1], Danev Slav[2] and Lakey Jonathan RT[1]*

[1]Department of Surgery and Biomedical Engineering, University of California Irvine, California, USA.

[2]Medeia Inc, Santa Barbara, CA, USA.

*Correspondence:
Jonathan RT Lakey, PhD, MSM, Department of Surgery, 333 City Blvd West, Suite 1600, Orange, CA 92868, USA, Phone: 1-949-824-8022, Fax: 1-714-456-6188.

Received: 02 May 2025; Accepted: 01 Jun 2025; Published: 10 Jun 2025

Citation: Casazza Krista, Danev Slav, Lakey Jonathan RT. Neural Signatures of Addiction: From Brain Mapping to Clinical Monitoring. Neurol Res Surg. 2025; 8(1): 1-8.

ABSTRACT

Chronic drug abuse induces progressive changes to brain anatomy and physiology leading to impairments in executive function, emotional regulation, memory, and reward processing. The assessment of the extent to which these changes affect cognitive function necessitates objective, neurophysiological tools. The advent of advanced technologies, such as the BrainView quantitative electroencephalography (qEEG) discriminant database by Medeia Inc is positioned to provide a comprehensive approach to understanding altered cognitive processing related to chronic drug abuse. This platform leverages key biomarkers like the N100, P300, and N400 event-related potentials (ERPs) to identify electrophysiological abnormalities in the disrupted key neural circuits adversely affected by drug abuse, particularly those involving the prefrontal cortex, amygdala, hippocampus, and striatum. qEEG allows for the detection of structural and physiological disruptions via assessment of electrophysiological alterations in ERPs. ERPs, such as diminished P300 amplitudes, reflect deficits in attentional and cognitive control. The BrainView system's ability to detect subtle changes in brain function makes it a critical tool for early diagnosis, monitoring the progression of cognitive dysfunction, and evaluating therapeutic interventions. With its extensive dataset, advanced statistical methods, and clinical focus, BrainView represents a transformative advancement in neurophysiology and neuropsychology, offering a comprehensive, efficient, and accurate solution for brain health assessments, ultimately paving the way for a new standard in clinical neuroassessment.

Keywords

BrainView, qEEG, Event-related potentials, Cognitive processing, Addiction.

Introduction

The repeated exposure to addictive substances (e.g., opioids, stimulants, and alcohol), disrupts the homeostasis of key neurotransmitter systems, including dopaminergic, glutamatergic, and GABAergic pathways, particularly within the mesocorticolimbic circuitry [1,2]. These disruptions fundamentally alter the neurobiological systems involved in reward, motivation, memory, and executive control. The consequent neuroadaptive response are associated with synaptic remodeling, neuroinflammation, and altered gene expression, contributing to compulsive drug-seeking behaviors and diminished cognitive flexibility [3,4]. Structural imaging studies have consistently demonstrated volumetric reductions in the prefrontal cortex, hippocampus, and amygdala among individuals with substance use disorders, which correlate with deficits in decision-making, emotional regulation, and memory [5-7]. Moreover, prolonged drug use impairs neurogenesis and disrupts white matter integrity, further compromising neural connectivity and function [8,9]. The understanding of drug abuse-related brain alterations is not only critical to understanding the chronic and relapsing nature of addiction but also serves to address the need for effective therapeutic strategies integrating both the neurobiological and behavioral dimensions of substance use disorders.

Psychoactive substances exert their influence by altering neurotransmission within the central nervous system, thereby modulating mood, cognition, perception, and behavior [1]. These drugs are broadly categorized based on their effects on

neural activity depressants, stimulants, and hallucinogens. Depressants, including opioids (e.g., morphine, heroin, fentanyl) and sedative-hypnotics (e.g., benzodiazepines and barbiturates), act primarily by enhancing inhibitory signaling through the gamma-aminobutyric acid (GABA) system or by binding to opioid receptors, leading to sedation, decreased alertness, and impaired cognitive function [10,11]. Chronic exposure to these substances can lead to neuroadaptive changes, including downregulation of receptor systems and alterations in synaptic plasticity, contributing to tolerance, dependence, and long-term cognitive impairments [12]. Moreover, the neuropsychological effects of such drugs underscore their classification as psychoactive agents, given their ability to acutely modify affective states and long-term brain structure and function. Stimulant drugs such as amphetamines, methamphetamine, cocaine, MDMA (ecstasy), and nicotine act primarily on the brain's reward and arousal systems, particularly the mesolimbic dopaminergic pathway, a key component of the limbic system responsible for mediating pleasure, motivation, and reinforcement [13]. These substances increase synaptic concentrations of dopamine, norepinephrine, and serotonin, leading to heightened alertness, euphoria, increased sociability, and confidence; however, they also cause adverse physiological effects including insomnia, anxiety, tachycardia, and hypertension [14,15]. Advances in neuroimaging and neurophysiological tools, particularly electroencephalography (EEG), have facilitated real-time, non-invasive monitoring of drug-induced alterations in brain activity, revealing characteristic patterns such as increased beta wave activity or altered event-related potentials (ERPs) associated with stimulant use[16]. As EEG technology becomes more accessible and affordable, it presents growing opportunities for both clinical assessment and research into the cognitive and neural consequences of stimulant abuse.

The brain–computer interface (BCI) represents a rapidly evolving field that enables direct communication between the brain and external devices by decoding neural activity, with EEG being the most commonly used non-invasive method due to its portability, temporal resolution, and accessibility [17]. While BCIs were initially developed for assistive technologies in clinical populations, they are now widely applied in cognitive neuroscience, rehabilitation, and even consumer-grade applications for healthy individuals [18]. EEG-based BCIs have proven particularly valuable in addiction research, where they are used to characterize alterations in cognitive processing and brain function among individuals with substance use disorders (SUDs) [18].

Spectral analysis of EEG signals has been employed to identify abnormalities in oscillatory activity associated with chronic drug use, such as increased theta power or reduced alpha coherence, which reflect disrupted cortical communication and cognitive control [19]. Complementarily, ERPs offer a temporally precise window into neurocognitive processes including selective attention, stimulus evaluation, and working memory. Components such as mismatch negativity, P300, and P600 have shown consistent alterations in individuals with opioid, cocaine, and methamphetamine dependence, with reduced amplitude and increased latency reflecting impairments in attention, motivation, and cognitive flexibility [20,21]. ERP paradigms using emotionally salient, deviant, or drug-related stimuli have provided crucial insights into cue-reactivity, craving, and relapse vulnerability, particularly during withdrawal and abstinence [22]. The P300 component, in particular, has emerged as a robust neural correlate of motivational salience and inhibitory control deficits in SUDs, making it a valuable marker for assessing treatment progress and relapse risk [23].

This paper highlights the application of signal processing before the brain mapping. Recent advancements in brain mapping have significantly enhanced the capacity to evaluate neurophysiological disturbances associated with SUDs, enabling more precise differentiation of drug-induced effects on brain function and their behavioral correlates. qEEG has emerged as a powerful non-invasive tool to detect abnormalities in neural oscillatory activity and brain connectivity in individuals with a history of drug use [24,25]. Studies employing full-brain qEEG mapping have consistently demonstrated that individuals with substance dependence exhibit a significantly higher prevalence of electrophysiological disturbances compared to both non-drug-using psychiatric controls and healthy individuals [26]. These abnormalities typically manifest as alterations in frequency bands, (e.g., increased theta and delta activity or reduced alpha and beta power) across frontal and central regions, which are implicated in executive dysfunction, impulsivity, and impaired emotional regulation [27]. Importantly, the severity and frequency of these abnormalities have been shown to correlate with the intensity and chronicity of substance use, suggesting a dose-response relationship between drug exposure and neurophysiological disruption [28]. This stratification capability positions EEG-based brain mapping as a valuable biomarker platform not only for diagnosis but also for staging severity and tracking neurocognitive recovery during treatment and abstinence. In this study, EEG was employed to monitor dynamic brain responses in ten male participants undergoing methadone maintenance therapy at Sadikin General Hospital. By recording brain activity before methadone administration and post-10 and 60 minutes, we aimed to capture real-time shifts in ERPs, particularly the P300 component, a neurocognitive marker associated with attention and stimulus evaluation. The results illuminate the modulatory effects of methadone on brain activity, providing insights into the neural mechanisms of craving and cognitive normalization in opioid-dependent individuals.

Methods

Study Subjects

Participants included 10 males currently undergoing rehabilitation treatment at an outpatient clinic. Prior to participation, all participants were interviewed by the study physician to ensure overall health to participate and not using medications that would alter results. A urinalysis was also conducted to validate absence of controlled substances. All participants provided written informed consent, and the experimental protocol was supported by the ethical clearance from RSHS Committee.

EEG

Experimental Design and Procedure

The experiment consisted of three EEG recording sessions conducted at baseline (before), 10 minutes after, and 1 hour after methadone consumption. These time points were selected to capture immediate and short-term neurophysiological changes in response to methadone administration.

EEG Data Acquisition

EEG was employed to measure and record electrical brain activity in response to visual stimuli. EEG signals were acquired using scalp electrodes positioned according to the international 10–20 system and affixed using conductive paste to ensure optimal contact and signal fidelity (Figure 1). Electrode impedance was maintained below 5 kΩ across all sessions.



Figure 1: An illustration of a BrainView setup for an EEG test, where brain electrical activity is measured during a qEEG.

Participants were seated in a sound-attenuated, dimly lit room and instructed to minimize movement while passively viewing a randomized sequence of visual stimuli on a computer monitor (Figure 2). These stimuli included both drug-related and neutral images. To engage selective attention and cognitive processing, participants were instructed to silently count the drug-related stimuli.

Figure 2: An image of the BrainView Neural Scan System developed by Medeia Inc. The BrainView system is portable, easy-to-use, and non-invasive. The BrainView system is a 21-channel EEG/ERP amplifier with a dedicated laptop and testing supplies. The system utilizes high-quality circuit boards and components to allow for high-quality brain measurements, as well as essential heart rate variability data.

Electrode Montage

EEG recordings were obtained from a subset of cortical sites: Fp1, Fp2, F7, F3, Fz, F4, F8, P3, and P4. These regions were selected for their established roles in attention, executive function, and visual processing. Synchronization between stimulus presentation and EEG data acquisition was achieved through digital triggers, ensuring precise temporal alignment. Recorded EEG segments were visually inspected, and only artifact-free data were retained for further analysis.

Integration of BrainView Platform

In addition to traditional EEG acquisition, a subset of sessions utilized the BrainView platform (Medeia Inc.), a rapid, portable, and cloud-integrated system for automated EEG and ERP Analysis. BrainView offers a streamlined 25-minute protocol to assess cognitive brain function, integrating ERP components such as N100, P300, and N400 with cloud-based analytics for comparison against normative reference data (described in more detail in ERP Core Components section). BrainView's portability and automation enabled consistent, real-time analysis across different environments, enhancing the practicality of ERP assessment in clinical and field settings. This integration allowed for rapid, objective evaluation of sensory, attentional, and cognitive function, complementing the more extensive EEG recordings.

Core ERP Components and Their Functions in BrainView

BrainView provides precise, millisecond-level quantification of ERP amplitudes and latencies, offering high-resolution insights into real-time brain responses. This facilitates rapid and clinically meaningful interpretation of sensory, attentional, and cognitive function, streamlining neurocognitive assessment and supporting data-driven clinical decision-making.

- **N100 (Auditory Sensory Processing):** The N100 is a negative-going waveform peaking approximately 100 milliseconds following an auditory stimulus, representing early-stage sensory processing. BrainView assesses this component by comparing responses to standard (softer) and deviant (louder) tones, enabling evaluation of auditory system responsiveness and temporal accuracy in sensory processing.
- **P300 (Attention Allocation):** Peaking around 300 milliseconds post-stimulus, the P300 is a positive deflection associated with attention and stimulus evaluation processes. BrainView analyzes both amplitude and latency of the P300, identifying potential abnormalities such as dual peaks that may indicate disruptions in attentional control or cognitive engagement. Its temporal stability makes it a reliable marker of attentional function.
- **N400 (Semantic Processing):** The N400 emerges roughly 400 milliseconds after the onset of a semantic stimulus, such as a word, and is indicative of cognitive processes related to language comprehension and contextual integration. BrainView evaluates responses to congruent and incongruent

word pairings, with the N400 typically exhibiting a wider temporal span than earlier ERP components, reflecting deeper cognitive processing demands.

ERP Feature Quantification: Amplitude and Latency

- **Amplitude:** Measured in microvolts (μV), amplitude reflects the strength of neuronal activation, influenced by the number and synchrony of activated cortical neurons. While higher amplitudes may indicate greater engagement, excessive amplitudes can signal dysfunctional overactivation, as seen in conditions like sensory hypersensitivity.
- **Latency:** Latency denotes the time (in milliseconds) taken for a waveform to reach its peak, serving as a measure of processing speed. Shorter latencies indicate more efficient neural transmission and cognitive performance, whereas delayed latencies may be linked to deficits such as impaired auditory processing or attentional delays.

Results

Raw data is the result of recording EEG signals that have not experienced signal processing or still contain noise and artifacts. The raw EEG data, recorded directly from participants, initially contained significant noise and artifacts due to muscle activity, eye movements, and environmental interference. These unprocessed signals are typically characterized by irregular waveforms that obscure meaningful neural patterns. To isolate relevant brain activity, the EEG signals were filtered using a bandpass filter ranging from 0.5 Hz to 30 Hz, which captures the frequency bands most associated with cognitive processes while excluding high-frequency noise and low-frequency drift.

To extract the event-related P300 component, wavelet decomposition was applied, a technique known for its effectiveness in isolating ERP components due to its ability to preserve both temporal and frequency information [29,30]. The resulting averaged P300 waveforms were analyzed to evaluate the impact of methadone on cognitive function.

Building on previous analytical techniques, our analysis showed a significant increase in P300 amplitude and a reduction in latency following methadone administration, suggesting enhanced cognitive processing efficiency [31,32]. These findings support the utility of P300 as a neurophysiological marker for assessing cognitive effects of pharmacological interventions. Pre-treatment measurements revealed attenuated P300 amplitudes and prolonged latencies, suggestive of impaired attentional engagement and slower cognitive processing (Figure 3).

Post-treatment data demonstrated a marked enhancement in P300 amplitude in response to stimuli, with mean values increasing from approximately 1.25 μV after methadone administration compared to a pre-treatment peak amplitude of 4.0 μV observed under heightened craving conditions. Additionally, the post-treatment P300 latency was significantly reduced (mean ≈ 240 ms) compared to the pre-treatment condition (mean ≈ 390 ms). Collectively, these findings indicate an improvement in stimulus evaluation speed and cognitive responsiveness. The elevated P300 during craving suggests a generalized increase in cortical excitability and impaired stimulus discrimination, consistent with attentional dysregulation. In contrast, the post-methadone state was characterized by a clearer differentiation between target and non-target stimuli, implying improved attentional focus and reduced interference from drug-related cues. Alterations in both the amplitude and latency of the P300 ERP suggests that methadone administration modulates neural mechanisms underlying cognitive control and attentional processes. Brain mapping further revealed that during the craving condition, cortical activity was more diffusely distributed, whereas post-administration activity became more localized, particularly in the frontal lobe a region commonly implicated in executive function (Figure 4).



Figure 3: Displays grand-averaged ERP waveforms following methadone administration. The x-axis represents time in seconds (s), relative to stimulus onset, while the y-axis represents amplitude in microvolts (μV). The prominent positive deflection peaking around 300 ms (0.3 s) is indicative of the P300 component, a cognitive ERP associated with attention and working memory. Alterations in P300 latency or amplitude post-methadone treatment may reflect the neurocognitive effects of methadone.

Interesting, post-methadone activation of one patient (Subject 1) shifted notably to the occipital lobe, likely reflecting increased visual processing in response to task stimuli. Additionally, both subjects exhibited changes in frontal lobe activation patterns, with a progression from superficial to deeper cortical layers following methadone intake, which was more prominent in Subject 1 and was visible in a comparison of topographic maps across the craving and post-treatment conditions (Figure 5). Analysis of the beta frequency band across EEG topographic brain maps revealed consistent spatial activation patterns along the second row of electrode placements, regardless of treatment condition. Importantly, EEG data acquired approximately 10 minutes post-methadone administration did not show substantial alterations in beta wave distribution compared to the craving state, suggesting that the effect of methadone on cortical beta activity may not be immediate and highlight the dynamic, time-dependent nature of its neurophysiological impact on brain function.



Figure 4: Topographical brain maps displaying z-scored EEG power spectral density across canonical frequency bands from 2–26 Hz during eyes-open condition following methadone administration. Each map represents averaged activity over a 2-Hz frequency bin (e.g., 2–4 Hz, 4–6 Hz, etc.) for a single subject or group-level average. The data are presented in 12 panels arranged by frequency band: Delta (2–4 Hz), Theta1 (4–6 Hz), Theta2 (6–8 Hz), Alpha1 (8–10 Hz), Alpha2 (10–12 Hz), SMR (12–14 Hz), Beta1 (14–16 Hz), Beta2 (16–18 Hz, 18–20 Hz), and Beta3 (20–22 Hz, 22–24 Hz, 24–26 Hz). Warmer colors (yellow) represent higher z-scored power relative to baseline/reference, while cooler colors (blue) represent lower z-scored power. Notable post-methadone changes include reductions in alpha and beta activity and increased delta/theta power in frontal and central regions, consistent with sedation and altered arousal states.



Figure 5: Power spectral density (PSD) plot illustrating frequency-specific changes in EEG activity during the eyes-open condition following methadone administration. The x-axis denotes frequency (Hz), and the y-axis reflects spectral power (arbitrary units). Colored bands indicate canonical EEG frequency ranges: Delta (1–4 Hz, maroon), Theta (4–8 Hz, purple), Alpha (8–12 Hz, green), SMR/Beta1 (12–20 Hz, dark blue), Beta2/Beta3 (20–30 Hz, light blue), and Gamma (30–40 Hz, grey). The black line represents post-methadone EEG PSD, while the yellow line reflects baseline or normative reference values. Methadone exposure is associated with enhanced low-frequency power (delta/theta) and a reduction in alpha and higher beta/gamma activity, consistent with central nervous system depressant effects.

Discussion

The overall relevance of these results resides in the potential use to enhance our understanding of how methadone modulates brain function, particularly in the context of addiction and cognitive control. Changes in P300 amplitude and latency provide objective, neurophysiological markers of attention and cognitive control. The observed increase in amplitude and reduction in latency following methadone administration suggest improved cognitive efficiency, which may reflect a normalization of attentional processes in individuals with opioid dependence. ERPs offer sensitive neurophysiological markers for assessing brain function and cognitive processing, with growing relevance in addiction research.

The N100, an early negative deflection peaking around 100 ms post-stimulus, reflects auditory sensory processing and attentional orientation, and is influenced by stimulus unpredictability and arousal [33,34]. The P300, peaking near 300 ms, indexes attentional allocation and working memory engagement, with P3a linked to involuntary attention and P3b to task-relevant processing. Both P3a and P3b show alterations in substance use disorders, where cognitive control and reward salience are dysregulated [35,36]. The N400, occurring around 400 ms, is tied to semantic processing and language comprehension, and is modulated by stimulus congruity and cognitive load; diminished N400 responses have been observed in individuals with impaired cognitive flexibility, a hallmark of addiction-related executive dysfunction [37]. Together, these ERP components provide quantifiable insights into how addiction alters sensory processing, attentional dynamics, and semantic integration, supporting their integration into neurodiagnostic tools for substance use disorders. The shift in brain activity from diffuse cortical activation during craving states to more localized frontal lobe activity post-treatment implies that methadone may help restore functional specificity in neural circuits involved in executive function. Frontal activation is particularly relevant, as this region is central to impulse control and decision-making—both critical in addiction recovery. The minimal change in beta activity within the first 10 minutes post-administration suggests that methadone's neurophysiological effects are time-dependent and may require longer latency to fully manifest. This emphasizes the need for temporally sensitive protocols in EEG-based monitoring of drug effects. The use of EEG-based metrics like P300 and beta band activity offers a non-invasive, cost-effective means to objectively assess treatment response and neural recovery over time. This could complement subjective measures of craving or cognitive function in clinical settings.

There are potential confounding variables that may have influenced the EEG results. These include participant movement during recording, recent consumption of substances such as caffeine (e.g., coffee, tea, soda), concurrent medication use, or residual effects of severe drug intoxication, despite pre-study eligibility assessment. Furthermore, EEG changes are not always localized to a single cortical region; rather, diffuse or global alterations in brain activity may occur in response to systemic disturbances such as acute drug toxicity or metabolic imbalances affecting neurotransmitter function. Such widespread changes can complicate the interpretation of region-specific EEG features and highlight the need for strict experimental control and comprehensive subject screening in neurophysiological studies of substance use.

Medeia Inc.'s BrainView ERP Platform represents a significant advancement in neurophysiological assessment, combining a normative qEEG database with clinically validated ERP biomarkers. This portable, FDA-cleared system enables objective measurement of key ERP components associated with sensory processing, attention, and higher-order cognitive functions. These biomarkers are particularly sensitive to neurofunctional impairments observed in substance use disorders, which are linked to structural and functional abnormalities in prefrontal and limbic regions. By integrating qEEG metrics (e.g., spectral power, coherence, and asymmetry Z-scores) with ERP data, the platform supports detection of subtle electrophysiological changes that may not be evident through behavioral assessment alone. The use of a large, demographically diverse normative dataset enhances its diagnostic precision and supports the establishment of robust clinical benchmarks. BrainView's discriminant functions allow for early identification of cognitive dysfunction, longitudinal monitoring of disease progression, and evaluation of treatment response, offering a scalable and objective tool for advancing personalized care in neuropsychiatric and addiction research.

We have previously contributed to the growing body of literature highlights the sensitivity of ERPs in the context of age-related cognitive changes, revealing their utility in differentiating normal from pathological aging. In healthy older adults, reductions in P300 amplitude and increases in latency reflect declining attention and processing speed, with some gender-based differences in these effects [38]. ERP components such as the P300 and N400 have shown sensitivity to age-related cognitive changes, with aging typically resulting in reduced amplitudes and increased latencies [39,40]. While these alterations are modest in healthy aging, they are significantly more pronounced in pathological conditions like Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD), where both P300 and N400 components demonstrate marked reductions in amplitude and delayed latencies, particularly in semantic processing tasks [41]. The N400, associated with semantic integration and memory retrieval, is often diminished in individuals with memory complaints compared to cognitively healthy older adults [41]. These ERP deviations may serve as potential biomarkers for early neurodegenerative changes and aid in differentiating normal from pathological aging. In psychiatric conditions such as schizophrenia, both P300 and N400 components are altered indicating deficits in attention and semantic processing [42]. Similarly, in substance use disorders, including alcohol and stimulant dependence, significant ERP abnormalities are observed. Individuals with alcohol use disorder show persistent reductions in P300 amplitude, even after abstinence, reflecting long-term cognitive impairment [43], while methamphetamine and cocaine users exhibit delayed or diminished N400 effects, highlighting disrupted semantic and executive processing [44,45].

Conclusion

Chronic drug abuse induces progressive changes to brain structure and function. The integration of advanced neurophysiological tools, such as the BrainView qEEG discriminant database, marks a significant advancement in clinical neuroassessment. Medeia Inc.'s innovative platform, which incorporates key biomarkers like N100, P300, and N400, is designed to not only identify electrophysiological abnormalities but also enhance our understanding of cognitive processing across a variety of neurological and psychiatric disorders. This cutting-edge system is capable of tracking subtle changes in brain function making it an invaluable tool for early diagnosis, monitoring disease progression, and evaluating treatment outcomes.

The strength of BrainView lies in its broad and diverse dataset, advanced statistical methods, and a clear focus on clinical applicability. This powerful solution enables clinicians to make more informed decisions about patient care, ultimately improving the accuracy and effectiveness of neurophysiological assessments. As the database continues to expand to include additional disorders, BrainView's ERP Platform represents a pivotal step toward more accurate, efficient, and comprehensive brain health assessments. By providing clinicians with the tools to better understand and monitor brain function, BrainView is poised to become a new gold standard in the fields of neurophysiology and neuropsychology, ushering in a new era of enhanced clinical care.

References

1. Koob GF, Volkow ND. Neurobiology of addiction a neurocircuitry analysis. Lancet Psychiatry. 2016; 3: 760-773.
2. Tomasi D, Wiers CE, Manza P, et al. Accelerated Aging of the Amygdala in Alcohol Use Disorders Relevance to the Dark Side of Addiction. Cereb Cortex N Y N 1991. 2021; 31: 3254-3265.
3. Koob GF. Antireward compulsivity and addiction seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction. Psychopharmacology Berl. 2017; 234: 1315-1332.
4. Nippert KE, Rowland CP, Vazey EM, et al. Alcohol flexible behavior and the prefrontal cortex Functional changes underlying impaired cognitive flexibility. Neuropharmacology. 2024; 260: 110114.
5. Waller R, Dotterer HL, Murray L, et al. White-matter tract abnormalities and antisocial behavior A systematic review of diffusion tensor imaging studies across development. NeuroImage Clin. 2017; 14: 201-215.
6. Cousijn J, Toenders YJ, van Velzen LS, et al. The relation between cannabis use dependence severity and white matter microstructure A diffusion tensor imaging study. Addict Biol. 2022; 27: e13081.
7. Evanski JM, Zundel CG, Baglot SL, et al. The First Hit to the Endocannabinoid System Associations Between Prenatal Cannabis Exposure and Frontolimbic White Matter Pathways in Children. Biol Psychiatry Glob Open Sci. 2024; 4: 11-18.
8. Robinson EA, Gleeson J, Arun AH, et al. Measuring white matter microstructure in 1,457 cannabis users and 1,441 controls A systematic review of diffusion-weighted MRI studies. Front Neuroimaging. 2023; 2: 1129587.
9. Zilverstand A, Huang AS, Alia-Klein N, et al. Neuroimaging Impaired Response Inhibition and Salience Attribution in Human Drug Addiction A Systematic Review. Neuron. 2018; 98: 886-903.
10. Volkow ND, Jones EB, Einstein EB, et al. Prevention and Treatment of Opioid Misuse and Addiction A Review. JAMA Psychiatry. 2019; 76: 208-216.
11. Kiyatkin EA, Choi S. Brain oxygen responses induced by opioids: focus on heroin fentanyl and their adulterants. Front Psychiatry. 2024; 15: 1354722.
12. Koob GF. Neurobiology of Opioid Addiction Opponent Process Hyperkatifeia and Negative Reinforcement. Biol Psychiatry. 2020; 87: 44-53.
13. Volkow ND, Blanco C. The changing opioid crisis development challenges and opportunities. Mol Psychiatry. 2021; 26: 218-233.
14. Gold MS, Baron D, Bowirrat A, et al. Neurological correlates of brain reward circuitry linked to opioid use disorder OUD Do homo sapiens acquire or have a reward deficiency syndrome? J Neurol Sci. 2020; 418: 117137.
15. Han BH, Palamar JJ. Multimorbidity Among US Adults Who Use Methamphetamine 2015-2019. J Gen Intern Med. 2022; 37: 1805-1807.
16. Ahmadlou M, Shirazi MY, Zhang P, et al. A subcortical switchboard for perseverative exploratory and disengaged states. Nature. 2025; 641: 151-161.
17. Zhang H, Jiao L, Yang S, et al. Brain-computer interfaces the innovative key to unlocking neurological conditions. Int J Surg Lond Engl. 2024; 110: 5745-5762.
18. Abiri R, Borhani S, Sellers EW, et al. A comprehensive review of EEG-based brain-computer interface paradigms. J Neural Eng. 2019; 16: 011001.
19. Ros T, Munneke MAM, Ruge D, et al. Endogenous control of waking brain rhythms induces neuroplasticity in humans. Eur J Neurosci. 2010; 31: 770-778.
20. Ramey T, Regier PS. Cognitive impairment in substance use disorders. CNS Spectr. 2019; 24: 102-113.
21. Strickland JC, Stoops WW, Banks ML, et al. Logical fallacies and misinterpretations that hinder progress in translational addiction neuroscience. J Exp Anal Behav. 2022; 117: 384-403.
22. Jafakesh S, Sangchooli A, Aarabi A, et al. Temporally dynamic neural correlates of drug cue reactivity response inhibition and methamphetamine-related response inhibition in people with methamphetamine use disorder. Sci Rep. 2022; 12: 3567.
23. Smith JL, Mattick RP, Jamadar SD, et al. Deficits in behavioural inhibition in substance abuse and addiction a meta-analysis. Drug Alcohol Depend. 2014; 145: 1-33.
24. Corriveau A, Yoo K, Kwon YH, et al. Functional connectome stability and optimality are markers of cognitive performance. Cereb Cortex N Y N 1991. 2023; 33: 5025-5041.
25. Ding K, Shen Y, Liu Q, et al. The Effects of Digital Addiction on Brain Function and Structure of Children and Adolescents A Scoping Review. Healthc Basel Switz. 2023; 12: 15.

26. Newson JJ, Thiagarajan TC. EEG Frequency Bands in Psychiatric Disorders A Review of Resting State Studies. Front Hum Neurosci. 2018; 12: 521.
27. Perera MPN, Gotsis ES, Bailey NW, et al. Exploring functional connectivity in large-scale brain networks in obsessive-compulsive disorder a systematic review of EEG and fMRI studies. Cereb Cortex N Y N 1991. 2024; 34: bhae327.
28. Volkow ND, Michaelides M, Baler R. The Neuroscience of Drug Reward and Addiction. Physiol Rev. 2019; 99: 2115-2140.
29. Demiralp T, Ademoglu A. Decomposition of event-related brain potentials into multiple functional components using wavelet transform. Clin EEG Electroencephalogr. 2001; 32: 122-138.
30. Samar VJ, Bopardikar A, Rao R, et al. Wavelet analysis of neuroelectric waveforms a conceptual tutorial. Brain Lang. 1999; 66: 7-60.
31. Wang GY, Kydd R, Wouldes TA, et al. Changes in resting EEG following methadone treatment in opiate addicts. Clin Neurophysiol Off J Int Fed Clin Neurophysiol. 2015; 126: 943-950.
32. Motlagh F, Ibrahim F, Rashid R, et al. Acute effects of methadone on EEG power spectrum and event-related potentials among heroin dependents. Psychopharmacology Berl. 2018; 235: 3273-3288.
33. Du X, Choa FS, Summerfelt A, et al. N100 as a generic cortical electrophysiological marker based on decomposition of TMS-evoked potentials across five anatomic locations. Exp Brain Res. 2017; 235: 69-81.
34. Marais AL, Roche-Labarbe N. Predictive coding and attention in developmental cognitive neuroscience and perspectives for neurodevelopmental disorders. Dev Cogn Neurosci. 2025; 72: 101519.
35. Bel-Bahar TS, Khan AA, Shaik RB, et al. A scoping review of electroencephalographic (EEG) markers for tracking neurophysiological changes and predicting outcomes in substance use disorder treatment. Front Hum Neurosci. 2022; 16: 995534.
36. Jurado-Barba R, Sion A, Martínez-Maldonado A, et al. Neuropsychophysiological Measures of Alcohol Dependence Can We Use EEG in the Clinical Assessment. Front Psychiatry. 2020; 11: 676.
37. Kräplin A, Joshanloo M, Wolff M, et al. The relationship between executive functioning and addictive behavior new insights from a longitudinal community study. Psychopharmacology Berl. 2022; 239: 3507-3524.
38. Young AT, Danev S, Lakey, et al. Advancing Clinical Neuroassessment The BrainView ERP Platform in Aging and Cognitive Dysfunction Diagnosis and Monitoring. Neurol – Res Surg. 2025; 8: 1-16.
39. Patel SH, Azzam PN. Characterization of N200 and P300 selected studies of the Event-Related Potential. Int J Med Sci. 2005; 2: 147-154.
40. Pergher V, Tournoy J, Schoenmakers B, et al. P300 Gray Matter Volume and Individual Characteristics Correlates in Healthy Elderly. Front Aging Neurosci. 2019; 11: 104.
41. Tanaka M, Yamada E, Mori F. Neurophysiological markers of early cognitive decline in older adults a mini-review of electroencephalography studies for precursors of dementia. Front Aging Neurosci. 2024; 16: 1486481.
42. Jellinger KA. Pathobiology of Cognitive Impairment in Parkinson Disease Challenges and Outlooks. Int J Mol Sci. 2023; 25: 498.
43. Park SE, Jeon YJ, Baek HM. Functional and Structural Brain Abnormalities and Clinical Characteristics of Male Patients with Alcohol Dependence. Brain Sci. 2023; 13: 942.
44. Mahoney JJ. Cognitive dysfunction in individuals with cocaine use disorder Potential moderating factors and pharmacological treatments. Exp Clin Psychopharmacol. 2019; 27: 203-214.
45. Yu Y, Huang Q, Liu X, et al. ERP-based evidence for the independent processing of structural and functional action semantics. Front Neurosci. 2025; 19: 1571972.

© 2025 Casazza Krista, et al.This article is distributed under the terms of the Creative Commons Attribution 4.0 International License